DAX24.332 +0,4%ESt505.360 +0,3%Top 10 Crypto15,80 +1,9%Dow45.010 +1,1%Nas21.020 +0,6%Bitcoin100.846 +0,1%Euro1,1750 -0,2%Öl69,13 +0,7%Gold3.366 -0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Tesla A1CX3T Deutsche Bank 514000 SAP 716460 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Lufthansa 823212 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y Bayer BAY001 Alphabet A (ex Google) A14Y6F BYD A0M4W9 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Vor EZB-Zinsentscheid: DAX stärker -- Tesla verfehlt Gewinnerwartungen - Umsatz leicht über Prognose -- D-Wave, Porsche, Amazon, Alphabet, Vodafone, BYD, Deutsche Bank, IBM im Fokus
Top News
DWS-Aktie in Grün: DWS mit kräftigem Gewinnplus DWS-Aktie in Grün: DWS mit kräftigem Gewinnplus
Zoll-Optimismus treibt an: DAX zeigt sich vor EZB-Zinsentscheid fest - Rekord in Sichtweite Zoll-Optimismus treibt an: DAX zeigt sich vor EZB-Zinsentscheid fest - Rekord in Sichtweite
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

PTC Therapeutics Aktie

Handeln
Aktien-Sparplan anlegen
39,60 EUR +0,60 EUR +1,54 %
FSE
47,11 USD +0,74 USD +1,58 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.3,17 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W0MW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS69366J2006

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPTCT

PTC Therapeutics Aktien News

DatumMeistgelesen
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
PR NewswireSephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Wer­bungPTC Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
PR NewswirePTC518 PIVOT-HD Study Achieves Primary Endpoint
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
PR NewswirePTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswirePTC Therapeutics to Participate in Upcoming Investor Conferences
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswirePTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
PR NewswirePTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
PR NewswirePTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
PR NewswireCHMP Maintains Negative Opinion on Translarna™ Reexamination
PR NewswirePTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
PR NewswirePTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics News

PTC Therapeutics News: auf dieser Seite finden Sie alle PTC Therapeutics News und Nachrichten zur PTC Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch PTC Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um PTC Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.